Shares of Aileron Therapeutics Inc (NASDAQ:ALRN) saw strong trading volume on Tuesday . 1,763,103 shares changed hands during trading, an increase of 496% from the previous session’s volume of 295,746 shares.The stock last traded at $0.45 and had previously closed at $0.43.
A number of research analysts have recently weighed in on the stock. Zacks Investment Research downgraded shares of Aileron Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, August 9th. ValuEngine upgraded shares of Aileron Therapeutics from a “hold” rating to a “buy” rating in a report on Thursday, August 1st. Finally, HC Wainwright restated a “buy” rating and set a $6.00 price target on shares of Aileron Therapeutics in a report on Monday, September 30th. One research analyst has rated the stock with a sell rating and four have given a buy rating to the stock. Aileron Therapeutics has an average rating of “Buy” and an average target price of $4.00.
The firm has a market cap of $11.96 million, a P/E ratio of -0.20 and a beta of 2.30. The business’s fifty day moving average price is $0.71 and its two-hundred day moving average price is $0.96. The company has a current ratio of 6.04, a quick ratio of 6.04 and a debt-to-equity ratio of 0.16.
In other news, SVP Kathryn Gregory bought 45,000 shares of the company’s stock in a transaction that occurred on Tuesday, August 13th. The shares were purchased at an average price of $0.65 per share, for a total transaction of $29,250.00. The purchase was disclosed in a document filed with the SEC, which is available through the SEC website. Also, SVP Vojo Vukovic bought 75,000 shares of the company’s stock in a transaction that occurred on Friday, August 16th. The stock was purchased at an average price of $0.59 per share, for a total transaction of $44,250.00. The disclosure for this purchase can be found here. Insiders purchased a total of 265,211 shares of company stock worth $207,650 in the last quarter. Insiders own 6.20% of the company’s stock.
An institutional investor recently raised its position in Aileron Therapeutics stock. Vanguard Group Inc. increased its position in Aileron Therapeutics Inc (NASDAQ:ALRN) by 261.6% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 333,005 shares of the company’s stock after acquiring an additional 240,910 shares during the quarter. Vanguard Group Inc. owned about 2.24% of Aileron Therapeutics worth $240,000 at the end of the most recent quarter. 26.00% of the stock is currently owned by institutional investors.
Aileron Therapeutics Company Profile (NASDAQ:ALRN)
Aileron Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing a novel class of therapeutics in the United States. The company's lead product candidate is ALRN-6924, a stapled peptide, which is in Phase I clinical trial for the treatment of advanced solid tumors or lymphomas; Phase IIa clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (MDS); and Phase IIb trial to treat AML/MDS in combination with cytosine arabinoside.
See Also: Why do companies engage in swaps?
Receive News & Ratings for Aileron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aileron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.